Erbitux fails another trial, threatening Merck's hoped-for expansion

It's another stumble for Erbitux. The cancer drug failed its second Phase III trial in months, Merck KGaA said, setting back the company's efforts to expand its use into stomach cancer. In May, Erbitux fell short in adjuvant treatment after colon-cancer surgery. Report